Anon. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 (1993), 646–650.
Office of the Surgeon General (US). Bone health and osteoporosis: a report of the Surgeon General, 2004, Office of the Surgeon General (US), Rockville, MD.
Hofbauer, LC, Schoppet, M, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004), 490–495.
Bekker, PJ, Holloway, DL, Rasmussen, AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19 (2004), 1059–1066.
McClung, MR, Lewiecki, EM, Cohen, SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006), 821–831.
Cummings, SR, San Martin, J, McClung, MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361 (2009), 756–765.
Bone, HG, Chapurlat, R, Brandi, ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98 (2013), 4483–4492.
Papapoulos, S, Chapurlat, R, Libanati, C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 27 (2012), 694–701.
Papapoulos, S, Lippuner, K, Roux, C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26 (2015), 2773–2783.
Ruggiero, SL, Dodson, TB, Assael, LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67 (2009), 2–12.
Shane, E, Burr, D, Ebeling, PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25 (2010), 2267–2294.
Shane, E, Burr, D, Abrahamsen, B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29 (2014), 1–23.
Genant, HK, Wu, CY, van Kuijk, C, Nevitt, MC, Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8 (1993), 1137–1148.
Reid, IR, Miller, PD, Brown, JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25 (2010), 2256–2265.
Brown, JP, Reid, IR, Wagman, RB, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res 29 (2014), 2051–2056.
Montagner, F, Kaftandjian, V, Farlay, D, Brau, D, Boivin, G, Follet, H, Validation of a novel microradiography device for characterization of bone mineralization. J Xray Sci Technol 23 (2015), 201–211.
Vittinghoff, E, McCulloch, CE, Woo, C, Cummings, SR, Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med 29 (2010), 1127–1136.
Dempster, DW, Compston, JE, Drezner, MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28 (2013), 2–17.
Dempster, DW, Daizadeh, N, Fahrleitner-Pammer, A, et al. Effect of 10 years of denosumab treatment on bone histology and histomorphometry in the FREEDOM extension study. J Bone Miner Res, 31(suppl 1), 2016, 323 (abstr).
Dempster, DW, Brown, JP, Yue, S, et al. Effects of up to 10 years of denosumab treatment on bone matrix mineralization: results from the FREEDOM extension. J Bone Miner Res, 31(suppl 1), 2016, LB-1163 (abstr).
Bone, HG, Hosking, D, Devogelaer, JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004), 1189–1199.
Black, DM, Schwartz, AV, Ensrud, KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296 (2006), 2927–2938.
Reginster, JY, Kaufman, JM, Goemaere, S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 23 (2012), 1115–1122.
Khan, A, Morrison, A, Cheung, A, Hashem, W, Compston, J, Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int 27 (2016), 853–859.
Adachi, JD, Bone, HG, Daizadeh, NS, et al. Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskelet Disord 18 (2017), 174–181.
Ferrari, S, Adachi, JD, Lippuner, K, et al. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 26 (2015), 2763–2771.
Bone, HG, Bolognese, MA, Yuen, CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96 (2011), 972–980.
Brown, JP, Roux, C, Törring, O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28 (2013), 746–752.
Anastasilakis, AD, Makras, P, Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27 (2016), 1929–1930.
Aubry-Rozier, B, Gonzalez-Rodriguez, E, Stoll, D, Lamy, O, Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27 (2016), 1923–1925.
Popp, AW, Zysset, PK, Lippuner, K, Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27 (2016), 1917–1921.
Brown, JP, Ferrari, S, Gilchrist, N, et al. Discontinuation of denosumab and associated vertebral fracture incidence: Analysis from FREEDOM and its Extension. J Bone Miner Res, 31(suppl 1), 2016, 1100 (abstr).
Black, DM, Reid, IR, Boonen, S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 27 (2012), 243–254.
Ominsky, MS, Libanati, C, Niu, QT, et al. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30 (2015), 1280–1289.
Seeman, E, Delmas, PD, Hanley, DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25 (2010), 1886–1894.
Liberman, UA, Weiss, SR, Bröll, J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 (1995), 1437–1443.
Black, DM, Thompson, DE, Bauer, DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85 (2000), 4118–4124.
Black, DM, Delmas, PD, Eastell, R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007), 1809–1822.
